MX375045B - Agonistas del receptor 5-ht2c y composiciones y metodos de uso. - Google Patents
Agonistas del receptor 5-ht2c y composiciones y metodos de uso.Info
- Publication number
- MX375045B MX375045B MX2018001380A MX2018001380A MX375045B MX 375045 B MX375045 B MX 375045B MX 2018001380 A MX2018001380 A MX 2018001380A MX 2018001380 A MX2018001380 A MX 2018001380A MX 375045 B MX375045 B MX 375045B
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- sleep
- addiction
- antipsychotic
- methods
- Prior art date
Links
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title abstract 2
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 208000016285 Movement disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010057342 Onychophagia Diseases 0.000 abstract 2
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000001613 Gambling Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 241000208125 Nicotiana Species 0.000 abstract 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 206010034158 Pathological gambling Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000021017 Weight Gain Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000036186 satiety Effects 0.000 abstract 1
- 235000019627 satiety Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000037322 slow-wave sleep Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
- 230000037221 weight management Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199382P | 2015-07-31 | 2015-07-31 | |
| PCT/US2016/044426 WO2017023679A1 (en) | 2015-07-31 | 2016-07-28 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001380A MX2018001380A (es) | 2018-06-15 |
| MX375045B true MX375045B (es) | 2025-03-06 |
Family
ID=56684262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001380A MX375045B (es) | 2015-07-31 | 2016-07-28 | Agonistas del receptor 5-ht2c y composiciones y metodos de uso. |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10272094B2 (https=) |
| EP (1) | EP3328835B1 (https=) |
| JP (1) | JP6789578B2 (https=) |
| KR (1) | KR20180031035A (https=) |
| CN (1) | CN108137508B (https=) |
| AU (1) | AU2016302755B2 (https=) |
| BR (1) | BR112018001707A2 (https=) |
| CA (1) | CA3002525A1 (https=) |
| EA (1) | EA039412B1 (https=) |
| HK (1) | HK1255850A1 (https=) |
| IL (1) | IL257107B (https=) |
| MA (1) | MA42527A (https=) |
| MX (1) | MX375045B (https=) |
| WO (1) | WO2017023679A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002525A1 (en) * | 2015-07-31 | 2017-02-09 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| CN110668951B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 一种盐酸司来吉兰的合成工艺 |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| US20220410894A1 (en) * | 2021-06-29 | 2022-12-29 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
| CN118302349A (zh) | 2021-10-14 | 2024-07-05 | 图森有限公司 | 用于操作自动驾驶车辆的系统和方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180733A (en) * | 1990-03-30 | 1993-01-19 | Abbott Laboratories | Biogenic amine uptake inhibitors |
| WO1992018005A1 (en) | 1991-04-16 | 1992-10-29 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| AU2003228485A1 (en) | 2002-04-12 | 2003-10-27 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| TW200307682A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| WO2005037796A1 (en) * | 2003-10-08 | 2005-04-28 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| JPWO2011071136A1 (ja) * | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US9556200B2 (en) * | 2012-03-06 | 2017-01-31 | Takeda Pharmaceutical Company Limited | Tricyclic compound |
| SG11201501894VA (en) * | 2012-09-14 | 2015-04-29 | Abbvie Inc | Tricyclic quinoline and quinoxaline derivatives |
| CA3002525A1 (en) * | 2015-07-31 | 2017-02-09 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
-
2016
- 2016-07-28 CA CA3002525A patent/CA3002525A1/en not_active Abandoned
- 2016-07-28 KR KR1020187005698A patent/KR20180031035A/ko not_active Withdrawn
- 2016-07-28 CN CN201680058247.6A patent/CN108137508B/zh not_active Expired - Fee Related
- 2016-07-28 AU AU2016302755A patent/AU2016302755B2/en not_active Ceased
- 2016-07-28 US US15/748,205 patent/US10272094B2/en active Active
- 2016-07-28 JP JP2018504658A patent/JP6789578B2/ja not_active Expired - Fee Related
- 2016-07-28 WO PCT/US2016/044426 patent/WO2017023679A1/en not_active Ceased
- 2016-07-28 MX MX2018001380A patent/MX375045B/es active IP Right Grant
- 2016-07-28 EA EA201890402A patent/EA039412B1/ru unknown
- 2016-07-28 HK HK18114926.0A patent/HK1255850A1/zh unknown
- 2016-07-28 MA MA042527A patent/MA42527A/fr unknown
- 2016-07-28 BR BR112018001707A patent/BR112018001707A2/pt active Search and Examination
- 2016-07-28 EP EP16751083.3A patent/EP3328835B1/en active Active
-
2018
- 2018-01-23 IL IL257107A patent/IL257107B/en active IP Right Grant
-
2019
- 2019-03-12 US US16/299,880 patent/US10624900B2/en active Active
-
2020
- 2020-04-14 US US16/848,013 patent/US11395824B2/en active Active
-
2022
- 2022-06-10 US US17/837,622 patent/US20230055376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1255850A1 (zh) | 2019-08-30 |
| JP2018522025A (ja) | 2018-08-09 |
| CA3002525A1 (en) | 2017-02-09 |
| MX2018001380A (es) | 2018-06-15 |
| KR20180031035A (ko) | 2018-03-27 |
| NZ739883A (en) | 2021-03-26 |
| US20200383993A1 (en) | 2020-12-10 |
| US10624900B2 (en) | 2020-04-21 |
| US10272094B2 (en) | 2019-04-30 |
| US20200078368A1 (en) | 2020-03-12 |
| MA42527A (fr) | 2021-04-07 |
| IL257107A (en) | 2018-03-29 |
| EA039412B1 (ru) | 2022-01-25 |
| EP3328835A1 (en) | 2018-06-06 |
| CN108137508A (zh) | 2018-06-08 |
| IL257107B (en) | 2021-03-25 |
| AU2016302755A1 (en) | 2018-03-15 |
| EP3328835B1 (en) | 2022-10-12 |
| BR112018001707A2 (pt) | 2018-09-18 |
| EA201890402A1 (ru) | 2018-09-28 |
| JP6789578B2 (ja) | 2020-11-25 |
| US11395824B2 (en) | 2022-07-26 |
| US20230055376A1 (en) | 2023-02-23 |
| CN108137508B (zh) | 2021-08-27 |
| WO2017023679A1 (en) | 2017-02-09 |
| US20180214455A1 (en) | 2018-08-02 |
| AU2016302755B2 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375045B (es) | Agonistas del receptor 5-ht2c y composiciones y metodos de uso. | |
| MX2020005898A (es) | Derivados de hexahidro-[1,4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. | |
| MX391442B (es) | Agonistas y composiciones del receptor 5-ht2c y métodos de uso. | |
| GEP20227387B (en) | Methods and compositions for treating sleep apnea | |
| EA201390855A1 (ru) | Сублингвальные пленки | |
| PH12019502018A1 (en) | Compositions, formulations and methods for treating ocular diseases | |
| EP3862362A3 (en) | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression | |
| EP3715457A3 (en) | Modulation of prekallikrein (pkk) expression | |
| MX2016012208A (es) | Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas. | |
| EA201691121A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
| MX2016004286A (es) | Biomarcadores de cancer y usos de los mismos. | |
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| MX2022003907A (es) | Compuestos y composiciones y usos de los mismos. | |
| TN2011000319A1 (en) | Substituted quinazoline compounds | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
| PH12016501864A1 (en) | Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators | |
| MY157319A (en) | Inhibitors of protein tyrosine kinase activity | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| MX363632B (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. | |
| AR098271A1 (es) | Agonistas del receptor 5-ht₂c | |
| WO2010083241A3 (en) | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders | |
| EA201791398A1 (ru) | Производные фумагиллола | |
| EA200801239A1 (ru) | Новые способы получения пиперазинильных и диазепанильных производных бензамина | |
| UA110978C2 (uk) | Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |